📰 Phoebe Mounts News
Phoebe Mounts News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Phoebe Mounts. Real-time updates on events, politics, business and more.
November 15, 2023
CRMD earnings call for the period ending September 30, 2023.
November 15, 2023
CorMedix Inc. (NASDAQ:CRMD) Q3 2023 Earnings Call Transcript November 14, 2023 CorMedix Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.21. Operator: Good afternoon, and welcome to CorMedix Third Quarter 2023 Earnings Conference Call. Today’s call is being recorded. [Operator Instructions] At this time, I would like to turn the conference over to […]
May 16, 2023
CRMD earnings call for the period ending March 31, 2023.
April 6, 2023
Operator: Greetings, and welcome to the CorMedix Inc. Fourth Quarter and Full Year 2022 Earnings Call. At this time, all participants are in a listen-only mode.
November 10, 2022
CRMD earnings call for the period ending September 30, 2022.
August 11, 2022
CRMD earnings call for the period ending June 30, 2022.
May 13, 2022
CorMedix Inc. (NASDAQ:NASDAQ:CRMD) Q1 2022 Earnings Conference Call May 12, 2022 16:30 ET Company Participants Daniel Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt...
August 28, 2021
SAN DIEGO, Aug. 28, 2021 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of CorMedix Inc. (NASDAQ: CRMD)...
August 20, 2021
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) and...
July 29, 2021
Share this article Share this article NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-14020, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CorMedix s...